• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重包装贝伐珠单抗中的高分子量聚集体。

High-molecular-weight aggregates in repackaged bevacizumab.

机构信息

Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado Denver, Aurora, Colorado 80045, USA.

出版信息

Retina. 2010 Jun;30(6):887-92. doi: 10.1097/IAE.0b013e3181d50cea.

DOI:10.1097/IAE.0b013e3181d50cea
PMID:20458261
Abstract

PURPOSE

The antivascular endothelial growth factor agents ranibizumab and bevacizumab are used to treat ocular neovascular diseases. There have been recent reports of sustained elevation of intraocular pressure after use of either agent, which we hypothesize could be because of high-molecular-weight aggregates.

METHODS

Enzyme-linked immunosorbent assay, size exclusion chromatography, and polyacrylamide gel electrophoresis were used to analyze repackaged bevacizumab syringes obtained from three outside compounding pharmacies and samples obtained directly from the original vial. Microflow imaging was used to examine particulate material within samples.

RESULTS

All syringes contained statistically similar amounts of protein, consisting of immunoglobulin (IgG) heavy and light chains (polyacrylamide gel electrophoresis). However, two of the three compounding pharmacies' batches had significantly less functional IgG in the solution (enzyme-linked immunosorbent assay). Additionally, the compounding pharmacies with the lowest IgG ( approximately 50%) also contained 10-fold the number of micron-sized particulate matter as measured by microflow imaging.

CONCLUSION

There are significant differences in IgG concentration measured from repackaged bevacizumab syringes. A trend exists for an increase in micron-sized protein aggregates with the decrease in IgG concentration. Large particulate matter within some samples may lead to obstruction of aqueous outflow and subsequent elevation in intraocular pressure. Additional studies are warranted to explore these findings.

摘要

目的

抗血管内皮生长因子药物雷珠单抗和贝伐单抗用于治疗眼部新生血管疾病。最近有报道称,两种药物使用后眼压持续升高,我们推测这可能是由于高分子量聚集物。

方法

采用酶联免疫吸附试验、分子筛层析和聚丙烯酰胺凝胶电泳分析从三家外部配制药房获得的重新包装的贝伐单抗注射器和直接从原始小瓶获得的样品。微流成像用于检查样品中的颗粒物质。

结果

所有注射器中均含有统计学上相似量的蛋白质,包括免疫球蛋白(IgG)重链和轻链(聚丙烯酰胺凝胶电泳)。然而,三家配制药房中的两批药物溶液中的功能性 IgG 明显减少(酶联免疫吸附试验)。此外,用微流成像测量,IgG 含量最低(约 50%)的两家配制药房的药物中含有 10 倍数量的微米级颗粒物质。

结论

从重新包装的贝伐单抗注射器中测量的 IgG 浓度存在显著差异。随着 IgG 浓度的降低,存在微米级蛋白聚集物增加的趋势。一些样品中的大颗粒物质可能导致房水流出受阻,随后眼压升高。需要进一步的研究来探讨这些发现。

相似文献

1
High-molecular-weight aggregates in repackaged bevacizumab.重包装贝伐珠单抗中的高分子量聚集体。
Retina. 2010 Jun;30(6):887-92. doi: 10.1097/IAE.0b013e3181d50cea.
2
Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.再包装贝伐珠单抗和雷珠单抗中的硅油微滴和蛋白聚集体:长期储存和产品处理不当的影响。
Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):1023-34. doi: 10.1167/iovs.10-6431. Print 2011 Feb.
3
Quality of bevacizumab compounded for intravitreal administration.用于玻璃体内给药的贝伐单抗的质量。
Eye (Lond). 2013 Sep;27(9):1090-7. doi: 10.1038/eye.2013.139. Epub 2013 Jun 21.
4
"High-molecular-weight aggregates in repackaged bevacizumab".重新包装的贝伐单抗中的高分子量聚集体
Retina. 2011 Apr;31(4):816-7; author reply 815. doi: 10.1097/IAE.0b013e3182109046.
5
Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.用于玻璃体内给药的一次性玻璃小瓶中重新包装的贝伐单抗(阿瓦斯汀®)的质量。
Arq Bras Oftalmol. 2017 Mar-Apr;80(2):108-113. doi: 10.5935/0004-2749.20170026.
6
Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab.贝伐珠单抗玻璃体腔内注射:亚可见颗粒对重新包装的贝伐珠单抗货架期的影响。
J Ocul Pharmacol Ther. 2019 Jul/Aug;35(6):372-375. doi: 10.1089/jop.2019.0042. Epub 2019 Jun 28.
7
CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?抗血管内皮生长因子药物污染用于玻璃体内注射:重新包装和新开发的注射器如何影响硅油液滴和蛋白聚集体的量?
Retina. 2018 Oct;38(10):2088-2095. doi: 10.1097/IAE.0000000000001809.
8
Storage stability of bevacizumab in polycarbonate and polypropylene syringes.贝伐单抗在聚碳酸酯和聚丙烯注射器中的储存稳定性。
Eye (Lond). 2015 Jun;29(6):820-7. doi: 10.1038/eye.2015.28. Epub 2015 Mar 27.
9
Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: In search of the main source of contamination.用于玻璃体内注射的重新包装的抗血管内皮生长因子中的硅油滴:寻找主要污染源。
Eur J Ophthalmol. 2020 Jul;30(4):774-779. doi: 10.1177/1120672118823133. Epub 2019 Jan 15.
10
Evaluation of compounded bevacizumab prepared for intravitreal injection.评估用于玻璃体内注射的复方贝伐单抗。
JAMA Ophthalmol. 2015 Jan;133(1):32-9. doi: 10.1001/jamaophthalmol.2014.3591.

引用本文的文献

1
Intraocular Pressure After Anti-Vascular Endothelial Growth Factor Injection in Eyes With a Mineralized Bruch's Membrane Caused by Pseudoxanthoma Elasticum.弹性假黄瘤所致矿化布鲁赫膜眼内抗血管内皮生长因子注射后的眼压
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):25. doi: 10.1167/iovs.66.11.25.
2
Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model.抗血管内皮生长因子(VEGF)药物在大鼠模型中经房水流出途径的清除情况
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):1. doi: 10.1167/iovs.66.6.1.
3
Preserved bevacizumab (Avastin®) eye drops for application in multidose containers - an in-vitro characterisation.
用于多剂量容器的保存型贝伐单抗(阿瓦斯汀®)滴眼液——体外特性研究
BMC Vet Res. 2025 Mar 1;21(1):129. doi: 10.1186/s12917-025-04592-4.
4
The Association of Primary Open Angle Glaucoma and Ocular Hypertension with Anti-VEGF Injections.原发性开角型青光眼和高眼压症与抗血管内皮生长因子注射的关联
Clin Ophthalmol. 2024 Dec 19;18:3861-3870. doi: 10.2147/OPTH.S482123. eCollection 2024.
5
Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types.在两种不同类型的聚丙烯注射器中复配和储存后,faricimab可保持物质完整性和无菌性。
Eye (Lond). 2025 Apr;39(5):943-950. doi: 10.1038/s41433-024-03511-5. Epub 2024 Dec 4.
6
Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies.探索抗血管内皮生长因子(VEGF)治疗与青光眼之间的关系:对管理策略的启示
J Clin Med. 2023 Jul 14;12(14):4674. doi: 10.3390/jcm12144674.
7
International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.国际创新与质量联盟:眼内药物非临床和早期临床开发的行业视角。
Clin Transl Sci. 2023 May;16(5):723-741. doi: 10.1111/cts.13480. Epub 2023 Feb 2.
8
Quantitative assessment of silicone oil release with siliconized and silicone oil-free syringes by microflow imaging microscopy.通过微流成像显微镜对使用硅化注射器和无硅油注射器的硅油释放进行定量评估。
Arq Bras Oftalmol. 2022 Jul 15;86(6). doi: 10.5935/0004-2749.2021-0320.
9
Effects of the Presence of Pseudoexfoliation on Intraocular Pressure and Retinal Nerve Fiber Layer Thickness in Patients with Macular Degeneration Receiving Intravitreal Ranibizumab.假性剥脱的存在对接受玻璃体内注射雷珠单抗治疗的黄斑变性患者眼压和视网膜神经纤维层厚度的影响。
Clin Pract. 2022 Jan 19;12(1):78-83. doi: 10.3390/clinpract12010009.
10
Aflibercept clearance through the drainage system in a rat model.阿柏西普在大鼠模型中经引流系统的清除情况。
Int J Retina Vitreous. 2021 Sep 8;7(1):53. doi: 10.1186/s40942-021-00322-8.